Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.
about
Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine TumorsRenal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatmentInfluence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotateAccuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy.Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images.The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Fast GPU-based Monte Carlo code for SPECT/CT reconstructions generates improved 177Lu images.Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
P2860
Q26783272-CEE26990-04DE-4B7C-9851-349A04748C53Q35244181-B5565624-F436-4E2A-8080-CDA8BB4BB5BFQ36484229-B6F6A551-701C-4DC8-8F4F-F669B2BE4771Q37608115-76554F05-8853-4380-B977-BCE535904760Q40036028-C138F22E-1AD7-4C5F-A21D-F9CDFA34E9BBQ41192086-035FF7D8-9B2C-44BD-B4B0-52855B3E5F03Q42345704-82BF06E9-7C63-4BA9-BE78-A5FE5B86F3BDQ47199533-8C1BD722-2653-43A5-939C-FA15F780C103Q48342806-E39A5681-8E27-4037-BA39-AD77AC8F313BQ54923034-91DC837C-46AC-471D-AA2A-5D8936D12CE4Q58695846-408251E8-8807-4B85-A2BE-829D9AA85DBC
P2860
Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Kidney dosimetry in ¹⁷⁷Lu and ...... tion method, and risk factors.
@en
Kidney dosimetry in ¹⁷⁷Lu and ...... tion method, and risk factors.
@nl
type
label
Kidney dosimetry in ¹⁷⁷Lu and ...... tion method, and risk factors.
@en
Kidney dosimetry in ¹⁷⁷Lu and ...... tion method, and risk factors.
@nl
prefLabel
Kidney dosimetry in ¹⁷⁷Lu and ...... tion method, and risk factors.
@en
Kidney dosimetry in ¹⁷⁷Lu and ...... tion method, and risk factors.
@nl
P2093
P2860
P50
P356
P1476
Kidney dosimetry in ¹⁷⁷Lu and ...... tion method, and risk factors.
@en
P2093
A Sarnelli
F Guerriero
M Cremonesi
P2860
P304
P356
10.1155/2013/935351
P407
P577
2013-06-20T00:00:00Z